The aim of this study was to investigate the long-term effectiveness of the combined therapy with pemafibrate and SGLT2 inhibitor for NAFLD patients who were “refractory to long-term SGLT2 inhibitor”. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.